PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

PolyPid Ltd. (NASDAQ:PYPD) has earned an average recommendation of “Moderate Buy” from the six research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $12.25.

A number of equities analysts recently commented on the stock. Weiss Ratings lowered shares of PolyPid from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of PolyPid in a research report on Wednesday, February 11th. Finally, Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th.

Hedge Funds Weigh In On PolyPid

Hedge funds have recently bought and sold shares of the business. AIGH Capital Management LLC increased its position in PolyPid by 26.1% during the fourth quarter. AIGH Capital Management LLC now owns 1,342,972 shares of the company’s stock worth $5,828,000 after acquiring an additional 277,844 shares during the period. ADAR1 Capital Management LLC bought a new position in PolyPid during the fourth quarter worth about $451,000. XTX Topco Ltd increased its holdings in PolyPid by 50.0% in the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after buying an additional 10,888 shares during the period. Jane Street Group LLC bought a new position in PolyPid in the 4th quarter valued at about $66,000. Finally, HighTower Advisors LLC bought a new position in PolyPid in the 4th quarter valued at about $44,000. 26.47% of the stock is owned by institutional investors.

PolyPid Price Performance

Shares of PYPD opened at $4.56 on Friday. The firm has a market capitalization of $87.00 million, a PE ratio of -2.02 and a beta of 1.41. The company’s 50-day moving average is $4.39 and its 200-day moving average is $4.23. PolyPid has a fifty-two week low of $2.44 and a fifty-two week high of $5.12.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings results on Wednesday, February 11th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). Analysts predict that PolyPid will post -1.5 earnings per share for the current fiscal year.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.